DBV Technologies S.A.
DBVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001613780
In the last 90 days, DBV Technologies S.A. insiders filed 0 open-market purchases and 1 sale; 78 institutions reported holding it in 13F filings for Q2 2026, worth $345.7M in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesDBVTF
Q4 2022 vs. Q3 2022
How the institutions holding DBV Technologies S.A. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 36 | 38 | +2 |
| Shares | 34.5M | 44.4M | +9.90M (+28.6%) |
| Value | $61.1M | $68.0M | +$6.85M (+11.2%) |
New holders (5)
Institutions that held DBV Technologies S.A. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Braidwell LP | 12,107,785 | $18.5M | 0.62% |
| Commodore Capital LP | 92,687 | $142.0K | 0.02% |
| Jane Street Group, LLC | 35,010 | $53.6K | 0.00% |
| RSM US Wealth Management LLC | 10,000 | $15.3K | 0.00% |
| Advisory Services Network, LLC | 4,000 | $6.12K | 0.00% |
Sold out (3)
Institutions that held DBV Technologies S.A. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| ExodusPoint Capital Management, LP | 181,050 | $320.0K |
| UBS Group AG | 4,992 | $9.00K |
| Wells Fargo & Company | 1,861 | $3.00K |